XBI

XBI remains in a clear Stage 4 decline with a medium-term bearish bias. Short-term conditions favor further downside, with price rejecting at the 9/20 EMA band and overbought RSI failing to find support. Under the Stable strategy, execute Sell Now on any relief into the EMA zone with disciplined participation.

• ↑Significant ETF inflows detected last week reflect positive investor sentiment.
• ↑Broad exposure across therapeutic, diagnostic, and research firms mitigates single-stock swings.
• ↓Biotech’s high R&D costs and research failures drive sector volatility.